Lutein Bioavailability From Fresh and Dried Beverages (METC-11/07)

Bioavailability of Lutein From a Lutein-enriched Egg-yolk-beverage and Its Dried Re-suspended Versions.

Macular pigment is composed primarily of the xanthophylls lutein and zeaxanthin, which are members of the carotenoid family. Epidemiological evidence indicates that a higher intake of lutein and zeaxanthin is associated with a lower risk to develop age-related macular degeneration (AMD). The lipid matrix of an egg yolk is an excellent vehicle for the efficient absorption of dietary lutein and it is possible to increase the natural lutein concentration in an egg yolk. A fresh lutein-enriched egg yolk beverage has been produced using these lutein-enriched egg-yolks. However, this beverage has a limited shelf life of maximum three weeks. Drying this fresh beverage extents the shelf live, however, this should be without loosing its functional properties concerning lutein bioavailability. At WUR-FBR two types of drying procedures have been evaluated resulting in two different dried product formulations, which need to be tested. The question is, whether the lutein bioavailability is not affected by different drying procedures.

Study Overview

• Status: Completed
• Conditions: Macular Pigment
• Intervention / Treatment: Dietary supplement: Fresh lutein-enriched egg-yolk beverage; Dietary supplement: Dried-1 lutein-enriched egg-yolk beverage; Dietary supplement: Dried-2 lutein-enriched egg-yolk beverage; Dietary supplement: Placebo beverage

• Study Type: Interventional
• Enrollment (Actual): 103
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 35 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• age 18-35 years
• BMI 18-25 kg/m2
• body weight should be stable for ≥6 months (with no weight gain/loss > 3 kg)

Exclusion Criteria:

• use of medication except incidental use of pain killers
• pulmonary inhalation medication and except usage of the contraceptive pill
• chronic diseases such as IBD or other stomach or bowel diseases
• not willing to discontinue consumption of vitamin supplements
• allergic to cow milk / dairy products/ eggs/ egg-rich products
• vegetarians
• smoking
• pregnant or breastfeeding women
• having donated blood (as blood donor) within 1 month prior to the screening
• visit or planning to do so during the study
• impossible or difficult venapuncture

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Serum lutein concentration	six weeks after intervention

Secondary Outcome Measures

Outcome Measure	Time Frame
Serum lipid concentrations	six weeks after intervention

Collaborators and Investigators

• Sponsor: Wageningen University

Study record dates

Study Major Dates

• Study Start: May 1, 2011
• Primary Completion (Actual): July 1, 2011
• Study Completion (Actual): July 1, 2011

Study Registration Dates

• First Submitted: July 20, 2011
• First Submitted That Met QC Criteria: July 21, 2011
• First Posted (Estimate): July 22, 2011

Study Record Updates

• Last Update Posted (Estimate): July 22, 2011
• Last Update Submitted That Met QC Criteria: July 21, 2011
• Last Verified: July 1, 2011

More Information

Terms related to this study

• Keywords: focus of study
• Other Study ID Numbers: EYEPOWDER